The composite transcription factor activating protein 1 (AP-1) integrates various mitogenic signals in a large number of cell types, and is therefore a major regulator of cell proliferation. In the normal human endometrium, proliferation and differentiation alternate in a cyclic fashion, with progesterone being largely implicated in the latter process. However, the effects of progesterone and the progesterone receptor (hPR) on AP-1 activity in the human endometrium are not known. To address this issue, HEC-1-B endometrial adenocarcinoma cells, which are devoid of hPR, were transfected with luciferase reporter constructs driven by two different AP-1-dependent promoters. Unexpectedly, cotransfection of hPR caused a marked induction of luciferase activity in the absence of ligand on both promoters. The magnitude of this induction was similar to that observed in response to the phorbol ester TPA. Addition of ligand reversed the stimulating effect of the unliganded hPR on AP-1 activity in these cells. These effects were specific for hPR, and were not observed with either human estrogen receptor or human glucocorticoid receptor. Furthermore, they strictly depended on the presence of AP-1-responsive sequences within target promoters. Finally, the described effects of hPR on AP-1 activity were shown to be cell-type specific, because they could not be demonstrated in SKUT-1-B, JEG-3, and COS-7 cells. To our knowledge this is the first report of an unliganded steroid receptor stimulating AP-1 activity. This effect and its reversal in the presence of ligand suggest a novel mechanism, through which hPR can act as a key regulator of both proliferation and differentiation in the human endometrium. Cellular proliferation and differentiation processes are regulated by extracellular factors, which, by binding to specific receptors, initiate intracellular signal cascades, and, thus, orchestrate the activity of transcription factors within the cell nucleus (1). Imbalances between proliferation-and differentiation-promoting signals have pathophysiological consequences, such as hyperplasia or even tumor formation (2). The composite transcription factor activating protein 1 (AP-1) is the prototype of a mitogen-activated transactivator, and its transcriptional activity is believed to reflect cell proliferation in many tissues (3-6). In contrast, nuclear receptors, such as the progesterone receptor (PR), represent classic examples of transcription factors that mainly govern cell differentiation (2, 6) . Interactions between these two types of transcription factors have only begun to be unraveled at the molecular level.
, and the C-terminal ligand-binding domain. This domain also contains an additional transactivation function (TAF-2) as well as signals for nuclear localization and heat shock protein (HSP) binding (11) (12) (13) . Although hPR is encoded by a single gene, it occurs in two distinct isoforms, hPR-A and hPR-B, which are generated by alternative promoter usage (14) . hPR-B is transcriptionally active on most progesterone-responsive promoters, whereas hPR-A seems to act in a more context-restricted fashion and can even antagonize the effects of hPR-B (15) .
In the unliganded state, hPR is anchored to a complex of HSPs, which prevents the receptor from binding to the DNA (16) . Ligand binding induces a conformational change in the receptor molecule that initiates a series of events including dissociation from the HSP complex, receptor phosphorylation, dimerization, and binding to specific DNA sequences termed PR response elements (13, 17) . This activation cascade was originally considered to be strictly steroid-dependent. However, several laboratories have recently reported an alternative mechanism, by which PR can be activated in the absence of ligand. Dopamine, for instance, has been shown to activate PR ligand independently, both in vitro and in vivo (18, 19) . Similar results were reported for the vitamin D and the retinoic acid receptors (20) . These effects probably involved phosphorylation of specific amino acid residues in the receptor molecule, since they were partially mimicked by the phosphatase inhibitor okadaic acid (21) . However (29, 30) and the thyroid receptors (31) .
The human endometrium represents a unique model to study possible interactions between hPR and AP-1, as it proliferates and differentiates in a cyclic fashion under the influence of estradiol and progesterone, respectively (2, 32 This element contains a modified TRE, which, in addition to AP-1 proteins, binds the transcription factor Oct-1 (34) . The plasmid PRE-tk81-luc was constructed by inserting two copies of the PRE from the tyrosine amino-transferase gene into tk81-luc. For pMSG-luc, the luciferase cDNA from pGEM-luc (Promega) was inserted immediately downstream of the mouse mammary tumor virus long terminal repeat in pMSG (Pharmacia). This promoter construct contains a TRE located 400 bp downstream from the 5' end of the full-length mouse mammary tumor virus long terminal repeat (35) . ERE-tk-luc was a gift from J. H. Segars (36) . IL-2-luc was donated by T. M. Williams (37) . The hPR expression vectors hPR-0 (hPR-B), hPR-3 (AF-1 deletion mutant of hPR-B), and hPR-5 (ligandbinding domain deletion mutant of hPR-B), all cloned into pSG5, were gifts from P. Chambon (11, 14) . pSG5 was used in mock-transfection for a total of 1.4 jig DNA per well. The expression vector encoding the non-DNA-binding hPR-B mutant (hPR-B-DBDcys) was a gift from K. Horwitz (38 (34, 35, 37) . In contrast, the activity of tk81-luc and PRE-tk81-luc, which do not contain TREs, was not significantly altered by cotransfected hPR-B.
Stimulation of AP-1 Activity by hPR Is Cell Type-Specific.
We were further interested to determine whether the observed effects of cotransfected hPR could also be elicited in other cell lines. The results of these experiments are shown in Fig. 4 . In SKUT-1-B and COS-7 cells, AP-1 activity was not induced by cotransfection of hPR-B. A minimal, yet not significant induction was seen in JEG-3 cells. Except for HEC-1-B cells, MPA had no effect on AP-1 activity in any of these cell lines.
The same results were obtained when TPA was added to the cell culture medium (data not shown). The observed effects were hPR-specific, and could not be shown with either hER or human glucocorticoid receptor. They were also promoter-specific and strictly depended on the presence of TREs or TRE-like sequences. Thus, the ARRE-1-, AP-l-tk81-, IL-2-, and mouse mammary tumor viruspromoter constructs were inducible by unliganded hPR, whereas the PRE-tk81-luc and tk81-luc were not. Among the cell lines studied, induction of AP-1 activity by transfected hPR was observed only in HEC-1-B endometrial adenocarcinoma cells. In SKUT-1-B cells, AP-1 activity was highly inducible by TPA, whereas transfection of hPR had no effect. In COS-7 and JEG-3 cells, neither TPA nor hPR induced AP-1 activity to a significant extent. The enhancing effect of the unliganded hPR on AP-1 transcriptional activity is, therefore, a cell type-specific phenomenon and has thus far only been observed in cells derived from the epithelial fraction of the human endometrium. At this time, one can only speculate as to how the hPR could interfere with the complex cascade leading to AP-1 activation in the absence of ligand and other external stimuli (e.g., dopamine). With respect to the underlying mechanism, our results allow several interpretations. One possible mechanism would be that the unliganded hPR inactivates a putative inhibitor of AP-1 activity in HEC-1-B cells. This interaction could involve either the hPR molecule itself or the HSP complex, which is usually associated with hPR in the absence of ligand (16, 17) . In this model, ligand binding would alter the conformation of the hPR molecule, thus abrogating its interaction with the inhibitory factor. However, the existence of a cell type-specific inhibitor of AP-1 action has not been reported as yet. Alternatively, the unliganded hPR could interact directly with the Jun/Fos complex to enhance its transcriptional activity. Again, the ligand-induced conformational change would reverse this interaction. Finally, the hPR molecule could be phosphorylated by protein kinase C, whose activity is exceptionally high in HEC-1B cells (unpublished observations). This could cause the hPR molecule to assume a conformation different from that induced by ligand, allowing it to enhance AP-1 transcriptional activity.
The other important finding is that progestins reverse the stimulating effect of the unliganded hPR. Anti-AP-1 activity of nuclear hormone receptors was previously reported for the glucocorticoid, androgen, thyroid hormone, and retinoic acid activity (25) (26) (27) (28) (29) (30) (31) 41) . The estrogen receptor clearly behaved differently from the other receptors, as it only inhibited AP-1 activity in a limited number of cases, but had a stimulatory effect in most systems, including human endometrial cells (6, 42, 43) . Previous evidence for hPR-mediated inhibition of AP-1 activity was presented by Shemshedini et al. (44) (25) . The mechanism by which nuclear receptors inhibit AP-1 is still a matter of dispute. Ligand-induced release of a putative inhibitory factor from the receptor/HSP complex is likely to be hPR-specific. In addition, both hPR and other nuclear receptors could form inactive complexes with Jun and Fos family members. The latter mechanism is suggested by results from crosslinking studies, showing physical association of the glucocorticoid receptor and c-Jun in vitro (28) . It is also interesting to note that the RU486-bound hPR-B inhibited AP-1 activity in this setting. This is in agreement with recent data showing inhibition of both AP-1 (46) and NF-KB (47) activity by RU486-GR. RU486, like progestin, promotes dissociation of hPR from the HSP complex (48) .
The control of cellular proliferation and differentiation in the human endometrium largely depends on the coordinate activation of estrogen and PR (2, 32) . In addition to their direct growth-modulating effects (49) , both receptors have been shown to antagonize each other at multiple levels (2, 50, 51). Our findings, based on results obtained in the HEC-1-B adenocarcinoma cell line, if extrapolated to the normal endometrium, would suggest a novel type of interaction, through which these receptors could regulate proliferation and differentiation in the human endometrium: It was previously reported that estrogens stimulate the expression of hPR (14) . In addition to the direct stimulatory effects of hER on AP-1 (6, 42, 43) , this would further enhance AP-1 activity in the first half of the menstrual cycle, when the majority of hPR molecules is unliganded. Under the influence of progesterone, this effect would be reversed in the second half of the cycle. By permanently elevating cellular hPR levels, unopposed estrogenic activity would keep the endometrium in the proliferative phase and, thus, lead to the development of endometrial hyperplasia and, finally, tumor formation.
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